Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powers, C.
Right arrow Articles by Gardner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powers, C.
Right arrow Articles by Gardner, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 47, Issue of November 22, 1996 pp. 30089-30095
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Modulation of JunD·AP-1 DNA Binding Activity by AP-1-associated Factor 1 (AF-1)*

(Received for publication, May 29, 1996, and in revised form, September 10, 1996)

Ciaran Powers , Henry Krutzsch and Kevin Gardner Dagger

From the Laboratory of Pathology, NCI, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

AP-1-associated factor 1 (AF-1), is a novel protein complex that dramatically enhances the assembly of JunD-containing dimers onto AP-1 consensus sites. We describe the partial purification of AF-1 from nuclear extracts of the T-cell line MLA 144 by ionic, hydrophobic and gel filtration chromatography. AF-1 is a DNA-binding protein composed of low molecular mass polypeptides of 7-17 kDa that exists in solution as a 34-kDa complex. JunD interactions with DNA are accelerated in the presence of AF-1 through the formation of a true tri-molecular complex with JunD dimers and DNA that assembles much more rapidly on DNA than JunD alone. DNA binding analysis of AF-1 interaction with JunD·AP-1 and DNA shows that AF-1 increases the DNA binding affinity of JunD for AP-1 sites over 100-fold. DNA cleavage footprint analysis of isolated AF-1·JunD DNA complexes shows that the ternary complex makes nearly twice as many contacts with DNA than JunD dimers alone. AF-1 interacts readily, but differentially with Jun homodimers and Jun·Fos heterodimers. These findings distinguish AF-1 as a significant protein-specific modulator of AP-1·JunD in T-cells.


INTRODUCTION

A central goal in the field of signal transduction biology is to elucidate the mechanisms through which short-lived signals, emanating from the surface of the cell, can be conveyed internally to effect long term changes in cellular behavior. Most of these changes are brought about by modulation of gene expression at the level of transcription (1). The AP-1 transcription factors are a ubiquitous class of gene regulatory factors that have a leading role in controlling widely diverse cellular processes (2, 3). This class of basic leucine zipper (bZip)1 DNA-binding proteins binds specifically to sequences related to the pseudopalindromic AP-1 consensus site (5'-TGA C/G TCA-3'), found in numerous genes responsive to the tumor-promoting phorbol esters like 12-O-tetradecanoylphorbol-13-acetate (TPA) (4, 5). Although this site is commonly referred to as the TPA-responsive element (TRE), it is regulated by a wide variety of signaling events at various genes (6, 7). AP-1 proteins either form Jun·Jun homodimeric complexes comprising the members of the Jun family (c-Jun, JunD, and JunB) or Fos·Jun heterodimers derived from the various Fos family members (c-Fos, Fra1, Fra2, FosB, and FosB2) (8, 9, 10, 11, 12, 13, 14, 15).

In addition to the well characterized modulation of AP-1 function by post-translation modifications such as phosphorylation and oxidation-reduction (16, 17), a great deal of flexibility in AP-1 function arises from the observation that AP-1 dimers can form multicomponent complexes with other unrelated transcription factors such as NF-AT (nuclear factor of activated T-cells), octamer, glucocorticoid receptor, and NF-kappa B, to effect site-specific up- or down-regulation of function (18, 19, 20, 21). Moreover, several other cellular and virally derived factors such as Jif, TAX, IP-1, and ABP have been shown to modulate the function of AP-1 and other bZip family members (22, 23, 24, 25, 26). The importance of AP-1 in the process of T-cell activation is well illustrated by the multiple roles it plays in the regulation of interleukin 2 expression. In addition to an independent TRE, the interleukin 2 promoter contains at least three or more regulatory elements that bind AP-1 coordinately with either NFATp, NFATc, or Oct-1 (27, 28).

In previous work, we isolated a cellular fraction from 0.8 M NaI T-cell nuclear extracts that contained a novel activity that dramatically stimulated JunD·AP-1 DNA binding activity (29). Within this fraction, significant stimulatory activity was found to reside in a set of 29-23-kDa polypeptides. In this current work we describe the identification, partial purification, and properties of a second active component of this 0.8 M NaI fraction as a multimeric DNA-binding protein composed of 7-17-kDa polypeptides. This factor, termed AP-1-associated factor 1 (AF-1), enhances JunD·AP-1 DNA binding by forming a tri-molecular complex with AP-1 dimers and DNA that binds with a 100-fold higher affinity than JunD alone. Interestingly, inducible AF-1·Jun complexes can be demonstrated in nuclear extracts from mitogen-stimulated T-cells that are partially inhibited in the presence of cyclosporine A.


EXPERIMENTAL PROCEDURES

Materials

Diisopropyl fluorophosphate, leupeptin, pepstatin A, PMSF, Hepes, Tween 20, BSA, NaI, and poly[d(I-C)] were purchased from Sigma. DEAE-53 cellulose was from Whatman. Protein A-agarose, Triton X-100, and Bio-Rex 70 resin were from Bio-Rad. Phenyl-Sepharose CL-4B was from Pharmacia Biotech Inc. Affinity-purified antibodies against JunD were prepared as described (29).

Cells and Media

The Jurkat human T-cell line and MLA144 cells (gibbon T-cell lymphoma) were grown in RPMI 1640 medium containing 10% fetal calf serum. Cells were harvested by centrifugation at 1000 × g for 10 min, and the pellets were washed three times with 3 volumes of cold PBS prior to preparation of nuclear extracts.

Preparation of Nuclear Extracts

Nuclear extracts were prepared from resting or mitogen-stimulated Jurkat T-cells by a extensive modification of the procedure described by Ohlsson and Edlund (30). Cells (approximately 1-3 × 109) were harvested and washed as decribed above. The cells were then resuspended in 5 volumes of Buffer A (10 mM KCl, 1.5 mM MgCl2, 4 mM BME, 0.5 mM PMSF, 10 µg/ml leupeptin, 10 mM Hepes, pH 7.5) and transferred to a 1.5-ml Eppendorf tube and allowed to stand for 10 min at 4 °C. The cells were then collected by centrifugation at 1000 × g for 10 min. at 4 °C. The supernatant was removed, and the cells were resuspended in 2 volumes of Buffer A and homogenized with 16 strokes of a Teflon pestle (fitted for 1.5-ml Eppendorf tubes) driven at 1500 rpm by a hand-held 0.75-hp power drill. Nuclei were collected by centrifugation at 1000 × g for 10 min at 4 °C, and the supernatant was removed. The isolated nuclei were resuspended in 5 volumes of Buffer B (0.2 mM EDTA, 4 mM BME, 0.5 mM PMSF, 10 µg/ml leupeptin, 20% glycerol, 20 mM Hepes, pH 7.5). 4 M ammonium sulfate, pH 7.9, was added to yield a final concentration of 0.3 M, and the suspension was allowed to incubate at 4 °C with gentle rocking for 30 min. The nuclear suspension was then clarified by centrifugation at 100,000 × g for 60 min at 4 °C. The resulting supernatant was quickly recovered prior to re-swelling of the nuclear pellet and assayed directly for DNA binding activity.

Preparation of Anti-JunD Antibody Immunoaffinity Column

10 mg of anti-JunD, prepared as described previously (29), was bound to 2 ml of protein A-agarose in buffers containing PBS, 0.2% Triton X-100, and 0.5 mM PMSF at 4 °C for 1 h. The antibody-coated agarose beads were washed into buffers containing 100 mM Hepes, pH 8.2, and chemically cross-linked by incubation with 10 mM ethyleneglycol bis-(succinimidylsuccinimate) for 1 h at room temperature. The column was quenched by washing the beads with 5 volumes of 1 M Tris-HCl and washed successively with 100 ml of buffer (containing M urea, 1% Triton X-100, 0.1 M glycine, 1 mM sodium azide), 200 ml of buffer (containing 0.5 M NaCl, 1 mM sodium azide, 10 mM Hepes, pH 7.5 at 4 °C), and finally equilibrated with 5-6 column volumes of buffer (containing PBS, 0.2% Triton X-100, and 1 mM sodium azide). A second nonspecific (anti-glutathione S-transferase antibody) antibody column was prepared from 10 ml of protein A-agarose and 30 mg of anti-GST antibodies.

Immunoaffinity Purification of JunD from T-cells

Nuclear extracts of MLA 144 T-cells were prepared as described previously (29), and dialyzed against PBS, 0.2% Triton X-100, 0.5 mM PMSF, and 1 mM azide, pH 7.5, for 3 h at 4 °C. The extract was then passed over a 10-ml anti-GST column, and the resulting flow-through was then passed over a 2-ml (5 mg/ml) anti-JunD affinity column. After washing successively with 25 column volumes each of 200 mM NaCl, 10 mM Hepes; 500 mM NaCl, 10 mM Hepes, pH 7.5; and 1 M MgCl2, the column was eluted with 4 M MgCl2, 0.05% Tween 20, and 1 mM sodium azide. Fractions (0.5 ml) were collected, screened for protein concentration, analyzed for JunD content by Western blot, pooled, and dialyzed overnight at 4 °C against 2000 volumes of buffer containing 10 mM Hepes, 50 mM NaCl, 8 mM BME, 0.05% Tween 20, 20% glycerol, and 1 mM sodium azide, pH 7.5. Cellular JunD prepared in this manner can be stored at -70 °C with no loss in DNA binding activity for over 16 months.

Purification of AF-1 from MLA144 Cells

Nuclei that had been sequentially extracted with 250 and 600 mM NaCl were prepared from 40L of MLA144 cells as described previously (29). The isolated nuclei were then resuspended in 180 ml of Buffer D (800 mM NaI, 0.2 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 4 µg/ml pepstatin, 20% glycerol, 4 mM BME, pH 7.5) and incubated with gentle rocking for 1 h at 4 °C. The suspension was then clarified by centrifugation at 300,000 × g for 3 h. The supernatant was collected and diluted to 0.4 M NaI by the addition of ice-cold Buffer D containing 0 mM NaI and adsorbed batchwise with gentle shaking for 30 min at 4 °C with 0.2 volume of DE53 previously equilibrated with 50 mM NaCl, 10 mM Hepes, 0.2 mM EDTA, pH 7.5. The DE53 suspension was centrifuged for 5 min at 1000 × g, and the supernatant was collected and passed over a 45-ml phenyl-Sepharose column sequentially equilibrated with 1 volume of distilled water, 1 volume of 100% ethanol, 2 volumes of n-butanol, 1 volume of 100% ethanol, and 1 volume of distilled water prior to equilibration in Buffer D (0.4 M NaI). The flow-through (approximately 350 ml) from the phenyl-Sepharose column was dialyzed overnight against 12 volumes of buffer E (50 mM NaCl, 0.05% Tween 20, 4 mM BME, 0.25 mM EDTA, 20% glycerol, 0.5 mM PMSF, and 20 mM Hepes, pH 7.5), at 4 °C. The dialyzed material was then applied to a 10-ml Bio-Rex 70 column equilibrated in buffer E and developed with a 100-ml 0.05-2 M NaCl linear gradient. Fractions (2 ml) were collected, and 1-µl aliquots were screened for the ability to form ternary complexes with immunopurified JunD by EMSA. Active fractions (peak reflecting conductivity between 0.5 and 0.8 M NaCl) were pooled and concentrated by ion exchange on a 2-ml Bio-Rex 70 column equilibrated in Buffer E and eluted with 250 mM NaCl Buffer E, followed by 0.8 M NaCl Buffer E. The 0.8 M NaCl material was adjusted to 0.5 M NaCl, applied to Superose 6 gel filtration column equilibrated in 0.5 M NaCl, 20 mM Hepes, 1 mM sodium azide. Fractions (0.5 ml) were collected, and 1-µl aliquots were analyzed by EMSA as decribed above. Active fractions were pooled and stored at -70 °C. AF-1 purified in this manner yields approximately 10 µg of protein that is stable at -70 °C for at least 12 months. The gel filtration column was calibrated with BSA (68 kDa, Stokes radius (RS) = 3.5 nm), ovalbumin (43 kDa, RS = 2.84 nm), chymotrypsinogen A (23.2 kDa, RS = 2.25 nm), and RNase A (13.6 kDa, RS = 1.8 nm).

Electrophoretic Mobility Shift Assays

EMSAs were performed by extended electrophoresis at 4 °C on 8% polyacrylamide gels for 5-16 h at 180-210 V. Binding was performed at 24 °C for 1 h (or as indicated) with either 0.2 ng (0.01 pmol) or indicated amounts of 32P-5'-end-labeled double-stranded oligodeoxyribonucleotide probe in a final volume of 11-14 µl in buffers containing 500 µg/ml BSA, 4 mM BME, 32-80 mM NaCl, 20% glycerol, 0.05% Tween 20, 0.2-0.8 µg of poly[d(I-C)], 20 mM Hepes, pH 7.5, and indicated amount of purified protein or nuclear. The oligonucleotide used in this study (other than those described in the figures) was as follows: GALV-TRE, 5'-AGCCAGAGAAATAGATGAGTCAACAGC-3'.

In Situ UV Cross-linking of Protein·DNA Complexes following EMSA

Protein·DNA complexes were separated by EMSA as described above. The electrophoretic apparatus was disassembled, and regions of the gel containing radioactive protein·DNA complexes were UV-irradiated with a 2,000-microwatt/cm2 (at 7.6 cm) shortwave UV hand lamp at a distance of 2.5 cm from the surface of the gel for 15 min. The gel was subsequently dried on filter paper (Whatman), and protein·DNA complexes were visualized by autoradiography, excised, and eluted in 0.1% SDS for 14 h. Eluted complexes were lyophilized and resuspended in an appropriate volume of SDS-PAGE buffer, separated on 15-20% SDS-PAGE gels, and dried prior to autoradiography.

In Situ DNA Footprint Analysis following EMSA

Copper chemical cleavage footprint analysis of DNA·protein complexes following EMSA was performed as described previously (31, 32), except products were separated on 16% acrylamide sequencing gels.

Antibodies

Antibodies to JunD and GST were prepared as described previously. Anti-Fos antibodies were a generous gift from Dr. Michael Iadarola (National Institutes of Health).

Recombinant Proteins

Recombinant JunD was prepared from extracts of Escherichia coli transformed with a plasmid construct (pGEX-JunD). The fusion protein, containing GST fused to the amino terminus of JunD was purified on a glutathione-agarose matrix and eluted with glutathione. Full-length bacterially expressed c-Jun was purchased from Promega. Truncated (139-270) bacterially expressed c-Fos was a generous gift from Dr. Tom Kerppola (University of Michigan, Ann Arbor, MI).

SDS-Polyacrylamide Gel Electrophoresis (PAGE)

SDS-PAGE was carried out in 0.2% (w/v) SDS with the buffers of Laemmli on 0.75-mm-thick 15-20% acrylamide gradient slabs with a 2.5-cm stacking gel. Protein bands were visualized after electrophoretic transfer to nitrocellulose membranes by staining with colloidal gold (Janssen Pharmaceutica, Amersham) according to the manufacturer's specifications.


RESULTS

Immunoaffinity Purification of JunD

Prior studies had identified an activity or activities, isolated from 0.8 M NaI extracts of MLA144 T-cell nuclei, that dramatically enhanced the DNA binding activity of JunD·AP1 (29). Similar non-Fos, non-Jun activity could also be found as contaminating components in DNA affinity-purified preparations of JunD (29, 33). The identification of these activities was based solely on the ability of the isolated fractions to stimulate specific binding of purified JunD to oligonucleotides containing the GALV-TRE sequence. To facilitate a more detailed study of this stimulatory activity in the current studies, it was therefore important to utilize preparations of purified JunD that were free of any contaminating components that could interfere with the assessment of regulated JunD-DNA binding activity. This required obtaining active preparations of purified JunD via means that were independent of DNA binding. Such requirements necessarily excluded DNA affinity-purified preparations of T-cell JunD as a suitable substrate for study. Although an attractive alternative, preparations of recombinant JunD contain very low percentages of active molecules. Due to their low DNA binding activity, these preparations must be used at very high protein concentrations. The possibility that the overwhelming excess of inactive molecules could interfere with proper assessment of the regulated function of the active population of JunD rendered recombinant sources of JunD even less suitable than the DNA affinity-purified JunD. JunD isolated from T-cell nuclear extracts by immunoaffinity purification was found to be the most useful and revealing substrate for the task of assessing the modulation of AP-1 DNA binding activity by various purified cellular components.

Cellular T-cell JunD was obtained at high purity from nuclear extracts of gibbon ape T-cells by immunoaffinity purification (see "Experimental Procedures"). Nuclear extracts rich in JunD DNA binding activity were generated from isolated gibbon ape T-cell MLA144 nuclei (29). After first processing over a nonspecific anti-GST antibody column, the extracts were passed over an affinity column that had been previously coupled to purified polyclonal anti-JunD antibodies at high concentration. Subsequently the column was washed with high salt buffers and eluted with 4 M MgCl2 (see "Experimental Procedures"). JunD purified in this manner was obtained in high purity and demonstrated the same predominant 43-kDa and 38-kDa polypeptides previously described in DNA affinity-purified JunD (29, 33). Moreover, this purified T-cell JunD was highly active, specific, and bound DNA at low protein concentrations. This immunoaffinity-purified form of JunD therefore was used throughout the purification and characterization of AF-1.

Purification and Properties of AF-1

AF-1 was purified from isolated T-cell nuclei by differential salt extraction followed by batchwise anion exchange chromatography, phenyl-Sepharose hydrophobic chromatography, gradient and stepwise cation exchange chromatography, ending with gel filtration chromatography (see "Experimental Procedures"). Isolated fractions were assayed for the ability to stimulate JunD DNA binding activity by EMSA. The peak of AF-1 activity in the final gel filtration step eluted with a molecular mass of approximately 34 kDa (see "Experimental Procedures"). SDS-PAGE analysis of peak fractions demonstrated a class of low molecular mass polypeptides ranging from approximately 7 to 17 kDa that consistently co-migrated with AF-1 activity (ternary complex formation with JunD and DNA; see Fig. 2A) at each step (Fig. 1, left). The apparent discrepancy in the native molecular mass of AF-1 and the size of the AF-1 polypeptides by SDS-PAGE suggest that AF-1 is multimeric, a highly elongated molecule, or both. EMSA analysis of purified AF-1 in the absence of JunD reveals an intrinsic DNA binding activity that is independent of added factors and can be detected as a rapidly migrating DNA·protein complex (Fig. 1, right).


Fig. 2. AF-1 polypeptide(s) form ternary complexes with JunD dimers and DNA. A, 8% acrylamide EMSA analysis of the addition of increasing amounts (2.5-20 ng) of AF-1 to a fixed amount (0.25 ng) of immunopurified JunD. Arrows show the positions of JunD binary complexes with DNA and AF-1·JunD ternary complexes as indicated. Electrophoresis was carried for 16 h to provide maximum resolution of JunD and AF-1·JunD complexes, as a result, free DNA and AF-1·DNA complexes were run off the gel and are, therefore, not present. B, competition analysis and comparison of DNA specificity of JunD and AF-1·JunD complexes for DNA. Purified JunD (0.25 ng) was incubated with 0.2 ng of 32P-labeled GALV-TRE in the presence or absence of 20 ng of AF-1 (as indicated) and 50 ng of the either wild type (59+60) or GALV-TRE sequences that were mutated by sets of 4 base transversion along the length of the sequence (see upper panel). The boxed area (upper panel) outlines the 7-base pair TRE consensus sequence. C, AF-1-dependent complexes with JunD contain AF-1 polypeptides. JunD (2 ng) was incubated with 8 ng of 32P-labeled GALV-TRE in the presence of absence of 20 ng of AF-1 as indicated. JunD·DNA and AF-1·JunD·DNA complexes were isolated by EMSA (lower panel) and cross-linked in situ by UV irradiation (see "Experimental Procedures"). DNA·protein adducts were excised, eluted, and analyzed by SDS-PAGE on a 15-20% gradient gel (upper panel). Protein·DNA adducts migrating at approximately 53 and 29 kDa in both lanes (arrowheads) represent DNA cross-linked JunD and JunD degradation products observed previously (29). Arrow indicates the position of the 19-kDa protein·DNA cross-linked adduct that is present exclusively in the AF-1·JunD·DNA complex.
[View Larger Version of this Image (26K GIF file)]



Fig. 1. Purification and properties of AF-1. A, left panel, SDS-PAGE analysis of purified AF-1. Arrows indicate position of polypeptides that consistently co-migrated with AF-1 activity. Asterisk indicates position of a contaminating polypeptide whose peak elutes with a smaller size (RS) than the AF-1 polypeptides (see "Experimental Procedures"). Right panel, EMSA analysis of purified AF-1 interaction with GALV-TRE DNA on a 4% acrylamide gel. Arrows indicate free DNA and DNA·protein complexes.
[View Larger Version of this Image (27K GIF file)]


AF-1 Forms a Stable Ternary Complex with JunD Dimers and DNA

The addition of increasing amounts of AF-1 to fixed amounts of JunD homodimers generates increased JunD DNA binding activity associated with the gradual formation of a ternary AF-1·JunD·DNA complex with significantly decreased mobility on native EMSA gels (see Fig. 2A). Quantitative Scatchard analysis of the formation of this complex by EMSA indicates that AF-1 increases the DNA binding affinity of JunD from 14 nM to 93 pM (data not shown). Competition with a series of TRE mutations in which transversions were generated at 4-base intervals along the length of the GALV-TRE AP-1 reveal that ternary AF-1·JunD·DNA and binary JunD·DNA complexes show similar specificity for the consensus TRE sequences (Fig. 2B, bottom panel).

In situ UV cross-linking of pre-formed JunD and AF-1·JunD complexes reveals the presence of a 19-kDa protein·DNA adduct exclusively in the AF-1·JunD complex (Fig. 2C, see arrow). The size of the 19-kDa adduct is consistent with the molecular mass of the polypeptides that are present in partially purified AF-1 and confirms that the AF-1·JunD complex is a ternary complex comprising JunD, AF-1, and DNA.

AF-1·JunD Ternary Complexes Make More Extensive Contacts with Flanking TRE Sequences Compared to JunD Alone

Pre-formed JunD and AF-1·JunD protein·DNA complexes were isolated by EMSA and digested in situ by copper cleavage (Fig. 3). Comparison of the cleavage protection produced by the two complexes shows that the AF-1·JunD complex extends the protection produced by JunD alone by at least 9 base pairs (Fig. 3). Protection is increased 7 base pairs in the 3' direction and at least 2 base pairs in the 5' direction.2


Fig. 3. AF-1·JunD ternary complexes make more extensive contacts with flanking TRE sequences than JunD alone. Upper panel, bound JunD·DNA and AF-1·JunD·DNA complexes were isolated by EMSA as in Fig. 2B and were subject to chemical copper DNA cleavage in situ (see "Experimental Procedures"). The DNA fragments were eluted and separated on 16% sequencing gels (lower panel). Sequences protected by JunD alone are indicated on the left. Those sequences protected by the AF-1·JunD complex are indicated on the right. Full base protection is indicated by bullet , and partial protection is indicated by open circle . Vertical arrows indicate the increase in protection of TRE flanking sequence by the AF-1·JunD complex.
[View Larger Version of this Image (38K GIF file)]


AF-1 Preferentially Forms Ternary Complexes with JunD and Increases the Rate of JunD Assembly onto DNA

When increasing amounts of JunD are added to a fixed concentration of AF-1 and DNA, a dramatic increase in DNA binding activity occurs with a concomitant decrease in the amount of binary AF-1·DNA complexes (Fig. 4A). The AF-1·JunD·DNA complexes show significantly higher binding than comparable amounts of JunD alone and the gradual decrease in the amount of binary AF-1·DNA complexes indicates that AF-1 has a much higher affinity and/or specificity for DNA complexed with JunD than for DNA alone.


Fig. 4. AF-1 preferentially forms complexes with JunD and increases the rate of JunD assembly onto TRE sequences. A, a fixed amount of AF-1 (2.5 ng) and increasing amount of JunD (0.25-40 ng) was added to 0.2 ng of 32P-labeled GALV-TRE and separated by EMSA on 8% acrylamide gels. JunD, AF-1, and JunD·AF-1 complexes are indicated by arrows. Electrophoresis was carried out so as not to lose the AF-1·DNA complexes and free 32P-labeled GALV-TRE; therefore, resolution of JunD and JunD·AF-1 complexes is limited. Asterisk indicates a rapidly migrating protein·DNA complex that appears variably after EMSA analysis of AF-1 and may represent a less stable monomeric form. B, purified JunD (0.25 ng) was incubated with 32P-labeled GALV-TRE with or without 2 µl of AF-1 (as indicated) for 1, 2, or 5 min prior to separation by EMSA on 8% acrylamide gels. Arrows show JunD and JunD·AF-1 complexes as indicated.
[View Larger Version of this Image (20K GIF file)]


Semi-quantitative analysis of the rate of assembly of binary JunD·DNA versus ternary AF-1·JunD·DNA complexes shows that AF-1·JunD complexes assemble onto DNA much more rapidly that JunD alone (Fig. 4B). Time-constrained binding of JunD to a TRE in the presence or absence of AF-1 shows that, while the binding of JunD to the TRE is maximum at 5 min, the formation of the AF-1·JunD complexes occurs much faster (less than 1 min). In fact, the rate of assembly of the AF-1·JunD complex is so rapid, it cannot be measured within the limitation of the assay. Interestingly, the dissociation rates of both the JunD and the AF-1·JunD complexes appear to be very similar (data not shown). Thus, AF-1 exerts its effects on JunD DNA binding by increasing the contacts it makes with DNA and these AF-1-dependent contacts promote a more rapid assembly of AP-1 onto DNA, while having little effect on the half-life of the complex.

AF-1 Shows Differential Binding Activity for Jun Homodimers and Jun·Fos Heterodimers

The extent of AF-1's ability to enhance AP-1 DNA binding activity is dependent on the context of the AP-1 members within the dimeric complex. When measured by EMSA at low concentrations, AF-1 readily stimulates the binding of both purified T-cell JunD and recombinant GST-JunD but has little effect on recombinant c-Jun (Fig. 5A). Similarly, while low concentrations of AF-1 stimulate the binding activity of both purified Jurkat T-cell JunD homodimers and JunD·Fos heterodimers, it shows little effect on the DNA binding activity of either recombinant c-Jun homodimer or c-Jun heterodimerized with c-Fos (Fig. 5B). Although these differences are much less pronounced at higher concentrations of AF-1 (data not shown), they indicate two important points about the mechanism AF-1 interaction. (i) AF-1 can associate with both Jun-containing homodimers and heterodimers containing Fos, and (ii) AF-1 interaction with AP-1 shows protein specificity and will differ depending on the context of the monomeric components present in the dimeric complex.


Fig. 5. AF-1 interacts differentially with Jun·Jun homodimers and Jun·Fos heterodimers. A, 0.2 ng of 32P-labeled GALV-TRE was incubated with 0.25 ng of JunD, 1 µg of GST-JunD, or 140 ng of c-Jun in the presence or absence of 0.125 µl of AF-1 as indicated and analyzed by EMSA on 8% acrylamide gels. B, 32P-labeled GALV-TRE was incubated with either 140 ng of c-Jun alone or 0.25 µl of immunoaffinity-purified Jurkat cell JunD in the presence or absence of 1 µl of AF-1 (lanes 1-4), or with the same additions in the presence of 50 nM c-fos (139-270) (lanes 5-8) and analyzed by EMSA on 4% acrylamide gels. Note faster migration of c-Jun·Fos and JunD·Fos heterodimers as opposed to the Jun homodimers.
[View Larger Version of this Image (20K GIF file)]


Inducible AF-1·JunD Complexes Are Present in Nuclear Extracts from PHA/PMA-stimulated Jurkat T-cells

EMSA analysis of crude nuclear extracts prepared from PHA/PMA-stimulated Jurkat T-cells reveals the presence of an inducible AP-1·TRE complex in addition to a slower migrating AP-1-containing complex that comigrates precisely with the AF-1·JunD complex reconstituted from purified JunD and AF-1 components (Fig. 6, A and B). Notably, this complex is highly induced above the levels detectable in unstimulated Jurkat T-cells. Moreover, the inducible AF-1·Jun complex is partially (approximately 33%) inhibited by prior treatment with 100 nM cyclosporine (Fig. 6A). Antibody supershift analysis of these complexes with anti-JunD and anti-Fos antibodies indicates that the predominant complex in uninduced T-cells is composed mainly of Jun homodimers, while the more strongly inducible and slower migrating AF-1·AP-1 complex contain both Jun and Fos (Fig. 6B). These data provide strong evidence that the AF-1·JunD complexes reconstituted from purified AF-1 and cellular JunD are representative of the in vivo complexes found in nuclear extracts from PHA/PMA-induced Jurkat T-cells.


Fig. 6. Inducible AF-1·JunD complexes are present in nuclear extracts from PHA/PMA-stimulated Jurkat T-cells. A, 0.2 ng of 32P-labeled GALV-TRE was incubated with 0.25 µl of immunoaffinity-purified Jurkat JunD with increasing amount of AF-1. Bound complexes were separated on the same EMSA gel with mixtures 0.2 ng of 32P-labeled GALV-TRE and 8 µg each of nuclear extracts derived from either resting Jurkat T-cells, T-cells stimulated with PHA/PMA, or T-cells stimulated with PHA/PMA in the presence of 100 ng/ml cyclosporine A as indicated. Arrows indicate positions of JunD and AF-1·JunD complexes in both purified proteins and crude nuclear extracts. B, 8 µg of nuclear protein from resting T-cells, PHA/PMA-stimulated T-cells, or cells stimulated in the presence cyclosporine A were incubated with 32P-labeled GALV-TRE with either no additions, 2 µl of anti-JunD antibodies, anti-Fos antibodies, or anti-glutathione S-transferase antibodies as indicated. Jun·AP-1 complexes that co-migrate with JunD, those complexes that co-migrate with AF-1·JunD, and antibody supershifted complexes are indicated by arrows.
[View Larger Version of this Image (41K GIF file)]



DISCUSSION

This report describes the identification, partial purification, and characterization of a novel protein, termed AF-1, that dramatically facilitates the assembly of AP-1 dimers onto DNA. At present, the actual stoichiometry of the AF-1 subunits in the AF-1·AP-1 complex remains undetermined until sufficient amounts of either purified or recombinant protein become available for quantitative study. Preliminary evaluation of AF-1 DNA binding activity in the absence of JunD or other AP-1 complexes indicates that AF-1 forms complexes with DNA that have little specificity in the absence of other factors (data not shown). The avidity that AF-1 shows for JunD·DNA complexes over DNA alone (see Fig. 4A) is consistent with this observation.

The ability of AF-1 to increase AP-1 DNA binding by primarily influencing the on rate of AF-1·JunD DNA binding, while having little or no effect on the half-life of the complex, could occur by two basic mechanisms. By the first model, AF-1 forms a binary complex with JunD dimers prior to binding to DNA. This binary complex could then assemble onto DNA in a more thermodynamically favorable fashion that could occur through stabilization of AP-1 dimer formation, relative lowering of the activation energy barrier for binding to DNA, or both. An essential component of this model is that AF-1 is capable of forming stable complexes with AP-1 dimers that can alter the dimer monomer equilibrium in the absence of DNA. Thus far we have not been able to detect any evidence of protein-protein interactions between AF-1 and either immunopurified or recombinant JunD. By a second model, AF-1 has insignificant affinity for JunD dimers alone but binds avidly to binary JunD·DNA complexes. Accordingly, JunD dimers would also be expected to bind with similar avidity to AF-1·DNA complexes. By this model either AF-1 or JunD binds preferentially to the extended DNA·protein surface created by its bound congener and DNA. This mode of interaction is very similar to that proposed for the tight interaction between calcineurin and the composite drug-protein surface created by the formation of cyclosporine-immunophilin complexes (34). These models are very similar to those proposed for the mechanism of action of TAX-1 (24).

The observation that AF-1 acts differentially with AP-1 dimers depending on the context of the individual AP-1 dimerization partners is quite intriguing. At the very least, it indicates that AF-1 interactions with dimeric AP-1 shows protein specificity. Whether or not the differential preference of AF-1 for dimers containing JunD, in comparison to those containing c-Jun, reflects a true "Jun family member preference" or is more a reflection of the differential stability of recombinant preparations of c-Jun protein remains to be investigated. It should be noted that these differences appear to be less striking when AF-1 is added to dimers of JunD or c-Jun at higher concentrations. The biological relevance of these differences will be better addressed when recombinant preparations of AF-1 become available for eucaryotic expression.

EMSA DNA binding analysis by extended electrophoresis on 8% polyacrylamide gels has added a new level of resolution to the analysis of AP-1 protein·DNA complexes. Under conventional conditions (4% acrylamide electrophoresis at 24 °C for 1 h), the protein·DNA complexes now known to have altered mobility and composition migrate as superimposed or dissociated complexes during electrophoresis. As a result, the AF-1·Jun·DNA ternary complexes appear indistinguishable from the binary Jun·DNA complexes. In addition to providing greater resolution, the electrophoretic separation of the protein·DNA complexes on 8% acrylamide at 4 °C provides a greater stability to the relative steady state ratio of binary and ternary complexes formed at equilibrium prior to electrophoresis. Nonetheless, at subsaturating concentrations of AF-1, this ratio appears to decay as the complexes fall apart during electrophoresis. The net result is an apparent increase in the relative amount of binary complexes at the completion of the electrophoresis. Such transitions are readily apparent in the EMSA analyses shown in Figs. 2A, 5, and 6A.

EMSA separation of crude nuclear extracts derived from Jurkat T-cells on 8% acrylamide reveals the presence of two distinct inducible TRE-binding complexes. Both complexes contain Jun. One co-migrates with purified AP-1 dimers and DNA, and the second complex migrates with a mobility that is identical to the AF-1·JunD complexes reconstituted from separately purified components (Fig. 6, A and B). The presence of AF-1 within T-cell activation inducible AP-1 complexes reveals a substantial role for AF-1 as modulator of AP-1 function in T-cells. The partial inhibition of inducible AF-1·Jun complexes by cyclosporine A treatment is quite intriguing and suggests that some step in the pathway to the assembly of the ternary AF-1·Jun complex may be modulated by cyclosporine A.

AF-1 represents one of two separate activities in the 0.8 M NaI extract of isolated T-cell nuclei that augment AP-1 DNA binding activity. The previously identified 29-23-kDa polypeptides found to augment JunD binding activity (see Ref. 29) show no evidence of ternary complex formation and do not alter the mobility of Jun complexes by extended EMSA electrophoresis on 8% acrylamide gels.3 By contrast, AF-1 shifts the mobility of Jun complexes and the AF-1-dependent complexes show increased contacts with sequences flanking the TRE consensus site. Currently, the mechanism of action of the 29-23-kDa polypeptides remains undefined.

It is not clear whether or not AF-1 will act as a negative transcriptional regulator or function positively. The observation that AF-1·Jun-like complexes are strongly induced during T-cell activation argues for a more prominent role as a positive regulator of AP-1 function. Like TAX-1, AF-1 could effect the DNA binding properties of multiple basic leucine zipper family members. The predominant role of AF-1 as an accessory protein that accelerates the rate of assembly of transcription factor complexes onto DNA could have profound influences on gene expression pathways that must generate a rapid response once threshold levels of active downstream signal transduction targets have been achieved. AF-1 could have a role in facilitating transcription factor entry and transcriptional co-factor function within the complicated and dynamic chromatin structure that surrounds rapidly inducible genes. Further purification, cloning, and functional characterization of AF-1 will provide critical insights into the mechanisms governing these important cellular processes.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Bldg. 10, Rm. 2N212, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-1055; Fax: 301-402-0043.
1   The abbreviations used are: bZip, basic leucine zipper; TPA, 12-O-tetradecanoylphorbol-13-acetate; TRE, TPA-responsive element; GALV, gibbon ape leukemia virus; EMSA, electrophoretic mobility shift assay; PAGE, polyacrylamide electrophoresis; Fra, Fos-related antigen; BME, beta -mercaptoethanol; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; BSA, bovine serum albumin; GST, glutathione S-transferase; AF-1, AP-1-associated factor 1; BME, beta -mercaptoethanol; PHA, phytohemagglutinin; PMA, phorbol myristate acetate.
2   Evaluation of the extension of the footprint in the 5' direction could not be reliably interpreted further than 2 bases due to the possibility of variable recovery of oligonucleotide cleavage products of that size.
3   C. Powers and K. Gardner, unpublished observation.

REFERENCES

  1. Maniatis, T., Goodbourn, S., and Fischer, J. A. (1987) Science 236, 1237-1245 [Medline] [Abstract/Free Full Text]
  2. Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157 [Medline] [Medline] [Order article via Infotrieve]
  3. Ransone, L. J., and Verma, I. M. (1990) Annu. Rev. Cell Biol. 6, 539-557 [Medline] [CrossRef]
  4. Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987) Cell 49, 729-739 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  5. McKnight, S. L. (1991) Sci. Am. 264, 54-64 [Medline]
  6. Lin, A., Smeal, T., Binetruy, B., Deng, T., Chambard, J. C., and Karin, M. (1993) Adv. Second Messenger Phosphoprotein Res. 28, 255-260 [Medline] [Medline] [Order article via Infotrieve]
  7. Engelberg, D., Klein, C., Martinetto, H., Struhl, K., and Karin, M. (1994) Cell 77, 381-390 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  8. Cohen, D. R., and Curran, T. (1988) Mol. Cell Biol. 8, 2063-2069 [Medline] [Abstract/Free Full Text]
  9. Curran, T., MacConnell, W. P., van Straaten, F., and Verma, I. M. (1983) Mol. Cell Biol. 3, 914-921 [Medline] [Abstract/Free Full Text]
  10. Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., and Tjian, R. (1987) Science 238, 1386-1392 [Medline] [Abstract/Free Full Text]
  11. Nakabeppu, Y., and Nathans, D. (1991) Cell 64, 751-759 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  12. Ryder, K., Lanahan, A., Perez Albuerne, E., and Nathans, D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1500-1503 [Medline] [Abstract/Free Full Text]
  13. Nishina, H., Sato, H., Suzuki, T., Sato, M., and Iba, H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3619-3623 [Medline] [Abstract/Free Full Text]
  14. Zerial, M., Toschi, L., Ryseck, R. P., Schuermann, M., Muller, R., and Bravo, R. (1989) EMBO J. 8, 805-813 [Medline] [Medline] [Order article via Infotrieve]
  15. Yu, L., Loewenstein, P. M., Zhang, Z., and Green, M. (1995) J. Virol. 69, 3017-3023 [Medline] [Abstract]
  16. Xanthoudakis, S., and Curran, T. (1992) EMBO J. 11, 653-665 [Medline] [Medline] [Order article via Infotrieve]
  17. Karin, M. (1994) Curr. Opin. Cell Biol. 6, 415-424 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  18. Jain, J., McCaffrey, P. G., Valge-Archer, V. E., and Rao, A. (1992) Nature 356, 801-804 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  19. Ullman, K. S., Northrop, J. P., Admon, A., and Crabtree, G. R. (1993) Genes Dev. 7, 188-196 [Medline] [Abstract/Free Full Text]
  20. Kerppola, T. K., Luk, D., and Curran, T. (1993) Mol. Cell Biol. 13, 3782-3791 [Medline] [Abstract/Free Full Text]
  21. Stein, B., Baldwin, A. S. J., Ballard, D. W., Greene, W. C., Angel, P., and Herrlich, P. (1994) EMBO J. 12, 3879-3891 [Medline] [Order article via Infotrieve]
  22. Monteclaro, F. S., and Vogt, P. K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6726-6730 [Medline] [Abstract/Free Full Text]
  23. Perini, G., Wagner, S., and Green, M. R. (1995) Nature 376, 602-605 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  24. Baranger, A. M., Palmer, C. R., Hamm, M. K., Giebler, H. A., Brauweiler, A., Nyborg, J. K., and Schepartz, A. (1995) Nature 376, 606-608 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  25. Auwerx, J., and Sassone-Corsi, P. (1991) Cell 64, 983-993 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  26. Busch, S. J., and Sassone-Corsi, P. (1990) Oncogene 5, 1549-1556 [Medline] [Medline] [Order article via Infotrieve]
  27. Jain, J., Loh, C., and Rao, A. (1995) Curr. Opin. Immunol. 7, 333-342 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  28. Avots, A., Escher, C., Muller-Deubert, S., Neumann, M., and Serfling, E. (1995) Immunobiology 193, 254-258 [Medline] [Medline] [Order article via Infotrieve]
  29. Gardner, K., Moore, T. C., Davis-Smyth, T., Krutzsch, H., and Levens, D. (1994) J. Biol. Chem. 269, 32963-32971 [Medline] [Abstract/Free Full Text]
  30. Ohlsson, H., and Edlund, T. (1986) Cell 45, 35-44 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  31. Sigman, D. S., Kuwabara, M. D., Chen, C. H., and Bruice, T. W. (1991) Methods Enzymol. 208, 414-433 [Medline] [Medline] [Order article via Infotrieve]
  32. Kuwabara, M. D., and Sigman, D. S. (1987) Biochemistry 26, 7234-7238 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  33. Quinn, J. P., Farina, A. R., Gardner, K., Krutzsch, H., and Levens, D. (1989) Mol. Cell Biol. 9, 4713-4721 [Medline] [Abstract/Free Full Text]
  34. Clipstone, N. A., Fiorentino, D. F., and Crabtree, G. R. (1994) J. Biol. Chem. 269, 26431-26437 [Medline] [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Chmura, X. Bai, M. Nakamura, P. Kandasamy, M. McGibney, K. Kuronuma, H. Mitsuzawa, D. R. Voelker, and E. D. Chan
Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells
Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L220 - L230.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Smith, I. Collins, G. V. R. Chandramouli, W. G. Butscher, E. Zaitseva, W. J. Freebern, C. M. Haggerty, V. Doseeva, and K. Gardner
Targeting Combinatorial Transcriptional Complex Assembly at Specific Modules within the Interleukin-2 Promoter by the Immunosuppressant SB203580
J. Biol. Chem., October 17, 2003; 278(42): 41034 - 41046.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Chaudhry, W. J. Freebern, J. L. Smith, W. G. Butscher, C. M. Haggerty, and K. Gardner
Cross-Regulation of T Cell Growth Factor Expression by p53 and the Tax Oncogene
J. Immunol., December 15, 2002; 169(12): 6767 - 6778.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. Poulaki, C. S. Mitsiades, A. M. Joussen, A. Lappas, B. Kirchhof, and N. Mitsiades
Constitutive Nuclear Factor-{kappa}B Activity Is Crucial for Human Retinoblastoma Cell Viability
Am. J. Pathol., December 1, 2002; 161(6): 2229 - 2240.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. C. Munshi, S. P. Treon, and K. C. Anderson
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Blood, May 29, 2002; 99(12): 4525 - 4530.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. Munshi, S. P. Treon, and K. C. Anderson
Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications
Blood, May 13, 2002; 99(11): 4079 - 4086.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Q. Li, K. Gardner, L. Zhang, B. Tsang, F. Bostick-Bruton, and E. Reed
Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells
J. Biol. Chem., September 4, 1998; 273(36): 23419 - 23425.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. G. Butscher, C. Powers, M. Olive, C. Vinson, and K. Gardner
Coordinate Transactivation of the Interleukin-2 CD28 Response Element by c-Rel and ATF-1/CREB2
J. Biol. Chem., January 2, 1998; 273(1): 552 - 560.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Yasui, W. Butscher, M. Cohen, N. Spriggs, R. Wersto, E. C. Kohn, L. Liotta, and K. Gardner
Selective Inhibition of Mitogen-induced Transactivation of the HIV Long Terminal Repeat by Carboxyamidotriazole. CALCIUM INFLUX BLOCKADE REPRESSES HIV-1 TRANSCRIPTIONAL ACTIVATION
J. Biol. Chem., November 7, 1997; 272(45): 28762 - 28770.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Olive, D. Krylov, D. R. Echlin, K. Gardner, E. Taparowsky, and C. Vinson
A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis
J. Biol. Chem., July 25, 1997; 272(30): 18586 - 18594.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. G. Butscher, C. M. Haggerty, S. Chaudhry, and K. Gardner
Targeting of p300 to the Interleukin-2 Promoter via CREB-Rel Cross-talk during Mitogen and Oncogenic Molecular Signaling in Activated T-cells
J. Biol. Chem., July 13, 2001; 276(29): 27647 - 27656.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. V. Kumar and L. R. Bernstein
Ten ERK-related Proteins in Three Distinct Classes Associate with AP-1 Proteins and/or AP-1 DNA
J. Biol. Chem., August 17, 2001; 276(34): 32362 - 32372.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powers, C.
Right arrow Articles by Gardner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powers, C.
Right arrow Articles by Gardner, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement